drugset / Trial / NCT06882785

A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

NCT06882785

Phase 3 Recruiting 250 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of KarXT in acutely psychotic Japanese adult participants with schizophrenia

Timeline

Start
2025-06-10
Primary completion
2028-09-23
Completion
2029-08-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Trospium Small molecule

Indications